Antiarrhythmic Drugs 2013: State of the Art
- 1.2k Downloads
Antiarrhythmic drugs are widely used, but are of modest efficacy and have important side effects. However, even with the advance of catheter ablation for atrial fibrillation and ventricular tachycardia, antiarrhythmic drugs remain an important tool for treating arrhythmias. Antiarrhythmic drug development has remained slow despite much effort given our limited understanding of what role various ionic currents play in arrhythmogenesis and how they are modified by arrhythmias. This review will focus on promising new antiarrhythmic drugs undergoing clinical investigation or currently approved for clinical use, including amiodarone analogues, agents with novel ionic targets, and new drug combinations.
KeywordsAtrial fibrillation Ventricular tachycardia Antiarrhythmic drugs Amiodarone analogues Dronedarone Celivarone Budiodarone Ranolazine Vernakalant Azimilide Ivabradine Drug synergy
Compliance with Ethics Guidelines
Conflict of Interest
Kapil Kumar and Peter J. Zimetbaum declare that they have no conflict of interest.
Human and Animal Rights and Informed Consent
This article does not contain any studies with human or animal subjects performed by any of the authors.
Papers of particular interest, published recently, have been highlighted as: • Of importance
- 1.• LafAuente-Lafuente C, Longas-Tejero MA, Bergmann JF, et al. Cochrane review 2012 antiarrhythmics for maintaining sinus rhythm after cardioversion of atrial fibrillation. Cochrane Database Syst Rev. 2012;5:CD005049. Excellent review of current clinically available antiarrhythmic drugs and their limitations.Google Scholar
- 2.The Atrial Fibrillation Follow-up Investigation of Rhythm Management (AFFIRM) Investigators. A comparison of rate control and rhythm control in patients with atrial fibrillation. N Engl J Med. 2002;347:1825–33.Google Scholar
- 6.Le Heuzey JY, De Ferrari GM, Radzik D, et al. A short-term, randomized, double-blind, parallel-group study to evaluate the efficacy and safety ofdronedarone versus amiodarone in patients with persistent atrial fibrillation: the DIONYSOS study. J Cardiovasc Electrophysiol. 2010;21:597–605.PubMedCrossRefGoogle Scholar
- 10.Morey TE, Seubert CN, Raatkainen MJP, et al. Structure-activity relationships and electrophysiological effects of short-acting amiodarone homologs in guinea pig isolated heart. J Pharmacol Exp Ther. 2000;297:260–6.Google Scholar
- 15.Kowey PR, Crijns HJGM, Aliot EM, et al. Efficacy and safety of celivarone, with amiodarone as calibrator, in patients with an implantable cardioverter-defibrillator for prevention of implantable cardioverter-defibrillator interventions or death: the ALPHEE Study. Circulation. 2011;124:2649–60.PubMedCrossRefGoogle Scholar
- 22.Roy D, Pratt C, Juul-Moller S, et al. Efficacy and tolerance of RSD1235 in the treatment of atrial fibrillation or atrial flutter: results of a phase III, randomized, placebo-controlled, multicenter trial [abstract]. J Am Coll Cardiol. 2006;47:10A.Google Scholar
- 23.Kowey PR, Roy D, Pratt CM, et al. Efficacy and safety of vernakalant hydrochloride injection for the treatment of atrial fibrillation after valvular or coronary artery bypass surgery. Circulation. 2007:114.Google Scholar
- 26.Cheng JWM, Rybak I. Pharmacotherapy options in atrial fibrillation: focus on vernakalant. Clin Med Therapeutics. 2009;1:215–30.Google Scholar
- 34.Tagarakis GI, Aidonidis I, Daskalopoulou SS, et al. Effect of Ranolazine in Preventing Postoperative Atrial Fibrillation in Patients Undergoing Coronary Revascularization Surgery. Curr Vasc Pharmacol. 2012 Nov 7. [Epub ahead of print].Google Scholar
- 57.• Burashnikov A, Sicouri S, Di Diego JM, et al. Synergistic effect of the combination of ranolazine and dronedarone to suppress atrial fibrillation. J Am Coll Cardiol. 2010;56:1216–24. First study to demonstrate synergistic effects between ranolazine and dronedarone in vitro.PubMedCrossRefGoogle Scholar